Register for email alerts and news feeds:
This journal | BMJ Group
rss
Journal of Neurology, Neurosurgery, and Psychiatry 2007;78:93-95; doi:10.1136/jnnp.2006.095661
Copyright © 2007 by the BMJ Publishing Group Ltd.

SHORT REPORT

Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours

C Daousi1, P M Foy2, I A MacFarlane1

1 Diabetes and Endocrinology Clinical Research Group, University Hospital Aintree, Liverpool, UK
2 Department of Neurosurgery, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK

Correspondence to:
Correspondence to:
C Daousi
Diabetes and Endocrinology Research Group, University Hospital Aintree, Clinical Sciences Centre, 3rd Floor, Lower Lane, Liverpool L9 7AL, UK; cdaousi{at}liverpool.ac.uk

ABSTRACT

Background: Thyrotropin (TSH)-secreting pituitary adenomas (TSHomas) are rare tumours that can be invasive. It has been suggested that thyroid surgery or radioiodine treatment should not be considered in patients with such tumours as these treatments may facilitate rapid and aggressive tumour expansion.

Aim: To study the effects of thyroid ablative treatment on tumour size and thyroid status in two patients with TSHomas in whom the size of the adenoma was clearly documented before treatment was started.

Methods: Patients studied were: (1) a female patient with a TSHoma who declined to undergo pituitary surgery and underwent a total thyroidectomy instead and (2) a male patient who opted for radioiodine treatment for his recurrent TSHoma. Changes in tumour size on serial magnetic resonance imaging scans, and restoration of euthyroidism were studied.

Results: No marked changes in tumour size or features of aggressiveness occurred in these patients over periods of 8 and 12 years. Euthyroidism was restored and maintained in both patients.

Conclusions: Ablative thyroid treatment can be a safe and successful option to treat TSHomas, but long-term and close follow-up of these patients is mandatory to ensure that the size and behaviour of the tumours do not change markedly.

Abbreviations: {alpha}SU, {alpha}-subunit; FSH, follicle-stimulating hormone; FT3, free tri-iodothyronine; FT4, free thyroxine; MRI, magnetic resonance imaging; TSH, thyrotropin; TSHoma, TSH-secreting pituitary adenoma


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Buchfelder, M, Weigel, D, Droste, M, Mann, K, Saller, B, Brubach, K, Stalla, G K, Bidlingmaier, M, Strasburger, C J, on behalf of the investigators of the German Pegvi, (2009). Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol 161: 27-35 [Abstract] [Full Text]  
  • Mittra, E. S., Niederkohr, R. D., Rodriguez, C., El-Maghraby, T., McDougall, I. R. (2008). Uncommon Causes of Thyrotoxicosis. JNM 49: 265-278 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest neurology and neurosurgery jobs

Neurology and neurosurgery jobs